A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts

Cancer Research

Volumn 59, Issue 5, 1999, Pages 1036-1040

  Polizzi, Donatella ^a   Pratesi, Graziella ^a   Tortoreto, Monica ^a   Supino, Rosanna ^a   Riva, Antonella ^b   Bombardelli, Ezio ^b   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INDENA S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CROSS RESISTANCE; DRUG EFFICACY; DRUG TOLERABILITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SOLUBILITY; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL DIVISION; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PACLITAXEL; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 0033105313     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Huizing, M. T., Sewberath Misser, V. H., Pieters, R. C., ten Bokkel Huinink, W. W., Veenhof, C. H. N., Vermorken, J. B., Pinedo, H. M., and Beijnen, J. H. Taxanes: a new class of antitumor agents. Cancer Invest., 13: 381-404, 1995.
2. Horwitz, S. B., Cohen, D., Rao, S., Ringel, L. Shen, H-J., and Yang, C-P. H. Taxol: mechanisms of action and resistance. Monogr. Natl. Cancer Inst., 15: 55-61, 1993.
3. Casazza, A. M., and Fairchild, C. R. Paclitaxel (Taxol) mechanisms of resistance. In: W. N. Hait (ed.). Drug Resistance, pp. 149-171. Boston: Kluwer Academic Publishers, 1996.
4. Appendino, G., Gariboldi, P., Gabetta, B., Pace, R., Bombardelli, E., and Viterbo, D. 14β-Hydroxy-10-deacetyl-baccatin III, a new taxane from Himalayan yew (Taxus wallichiana Zucc.). J. Chem. Soc. Perkin Trans. 1: 2925-2929, 1992.
5. Goldspiel, B. R. Clinical overview of the taxanes. Pharmacotherapy, 17: 110-125, 1997.
6. Distefano, M., Scambia, G., Ferlini, C., Gaggini, C., De Vincenzo, R., Riva, A., Bombardelli, E., Ojima, L. Fattorossi, A., Benedetti Panici, P., and Mancuso, S. Anti-proliferative activity of a new class of taxanes (14β-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int. J. Cancer. 72: 844-850, 1997.
7. Workman, P., Balmain, A., Hickman, J. A., McNally, N. J., Mitchison, N. A., Pierrepoint, C. G., Raymond, R., Rowlatt, C., Stephens, T. C., and Wallace, J. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br. J. Cancer. 58: 109-113, 1988.
8. Workman, P., Twentyman, P., Balkwill, F., Balmain, A., Chaplin, D., Double, J., Embleton, J., Newell, D., Raymond, R., Stables, J., Stephens, T., and Wallace, J. United Kingdom co-ordinaling committee on cancer research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br. J. Cancer, 77: 1-10, 1998.
9. Nicoletti, M. I., Lucchini, V., D'Incalci, M., and Giavazzi, R. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. Eur. J. Cancer, 5: 691-696, 1994.
10. Rose, W. C., Clarck, J. L., Lee, F. Y. F., and Casazza, A. M. Preclinical antitumor activity of water-soluble paclitaxel derivatives. Cancer Chemother. Pharmacol., 39: 486-492, 1997.
11. Sharma, A., Mayhew, E., Bolcsak, L., Cavanaugh, C., Harmon, P., Janoff, A., and Bernacki, R. J. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer. 71: 103-107, 1997.
12. Ise, W., Heuser, M., Sanders, K. H., Beck, J., and Gekeler, V. P-glycoprotein-associated resistance to taxol and taxotere and its reversal by dexniguldipine-HCl. dexverapamil-HCL, or cyelosporin A. Int. J. Oncol. 8: 951-956, 1996.
13. Zhan, Z., Scala, S., Monks, A., Hose, C., Bates, S., and Fojo, T. Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. Cancer Chemother. Pharmacol., 40: 245-250, 1997.
14. Gore, M. E., Levy, V., Rustin, G., Perren, T., Calvert, A. H., Earl, H., and Thompson, J. M. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br. J. Cancer, 72: 1016-1019, 1995.
15. Seidman, A. D. The emerging role of paclitaxel in breast cancer therapy. Clin. Cancer Res., 1: 247-256, 1995.
16. Markman, M., Hakes, T., Barakal, R., Curtin, J., Almadrones, L., and Hoskins, W. Follow-up of Memorial Sloan-Kettering Cancer referral center patients treated on National Cancer Institute treatment patients protocol 9103: paclitaxel in refractory ovarian cancer. J. Clin Oncol., 14: 796-799, 1996.
17. Clemons, M., Leahy, M., Valle, J., Jayson, G., Ranson, M., and Howell, A. Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Eur. J. Cancer, 33: 2183-2193, 1997.
18. Eisenhauer, E. A. Docetaxel: current status and future prospects. J. Clin. Oncol., 13: 2865-2868, 1995.
19. Alder, J. D., Jarvis, K. P., Marsh, K. C., Klein, L. L., and Clement, J. J. Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumours. Br. J. Cancer. 73: 560-564, 1996.
20. Zunino, F., Perego, P., Pilotti, S., Pratesi, G., Supino, R., and Arcamone, F. Role of apoplotic response in cellular resistance to cytotoxic agents. Pharmacol. Ther., 76: 177-185, 1997.
21. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
22. Debernardis, D., Siré, E. G., De Feudis, P., Vikhanskaya, F., Valenti, M., Russo, P., Parodi, S., D'Incalci, M., and Broggini, M. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res., 57: 870-874, 1997.
23. Gottlieb, T. M., and Oren, M. p53 in growth control and neoplasia. Biochim. Biophys. Acta, 1287: 77-102, 1996.
24. Hawkins, D. S., Demers, G. W., and Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56: 892-898, 1996.
25. Murphy, M., Hinman, A., and Levine, A. J. Wild-type p53 negatively regulates the expression of a microtubute-associated protein. Genes Dev., 10: 2971-2980, 1996.
26. 2/M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
27. Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Arbuck, S. G., and Donehower, R. C. Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol., 20: 1-15, 1993.
28. Van Gerven, J. M. A., Moll, J. W. B., van den Bent, M. J., Bontenbal, M., van der Burg, M. E. L., Verweij, J., and Vecht, C. J. Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur. J. Cancer. 30A: 1074-1077, 1994.
29. Moos, P. J., and Fitzpatrick, F. A. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc. Natl. Acad. Sci. USA, 95: 3896-3901, 1998.